デフォルト表紙
市場調査レポート
商品コード
972131

ニキビ治療薬市場:治療クラス別、処方別、タイプ別、ニキビタイプ別、および流通チャネル別:世界の機会分析と業界予測(2019年~2027年)

Acne Medication Market by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 278 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
ニキビ治療薬市場:治療クラス別、処方別、タイプ別、ニキビタイプ別、および流通チャネル別:世界の機会分析と業界予測(2019年~2027年)
出版日: 2020年09月30日
発行: Allied Market Research
ページ情報: 英文 278 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のニキビ治療薬の市場規模は2019年に118億6,590万米ドルとなりました。同市場は、2020年から2027年にかけ3.80%のCAGRで拡大し、2027年までに133億5,757万米ドルに達すると予測されています。

ニキビは、主に皮脂の過剰産生によって引き起こされる一般的な皮膚障害です。この中には、吹き出物として知られている病変の発生があります。ニキビは通常思春期に始まり、青年期に症状が悪化することがあります。重症度に応じてニキビ治療薬で治療することができます。ニキビの治療には、皮脂産生の減少、死滅した皮膚細胞の除去、経口薬の投与による細菌の死滅などがあります。ニキビ治療薬は直接塗布するもので、製剤に含まれている形、あるいは経口錠剤の形で服用されます。これらの薬は、炎症と油分の産生を減らすことによって機能します。また、バクテリアと戦い最終的に瘢痕を防ぎます。一般的なニキビ治療薬には、レチノイド、抗生物質、イソトレチノイン、過酸化ベンゾイルなどがあります。

世界のニキビ治療薬市場の成長は、ニキビの有病率の上昇によって推進されています。これは、ニキビ治療薬市場の成長に寄与する主要な要因です。さらに、市場の成長を促進する他の要因として、不健康な都市のライフスタイルやパイプラインに存在する強固なニキビ治療薬などがあります。ただし、ニキビ治療薬の使用に伴う副作用と代替治療の存在は、市場の成長を妨げます。逆に、副作用の少ない効果的な治療薬の開発と、未開拓の新興経済国における高い市場青山性が、市場の成長に豊富な成長機会を提供することが期待されます。

世界のニキビ治療薬市場は、治療クラス別、処方別、タイプ別、ニニキビタイプ別、流通チャネル別、および地域別に分類されます。治療クラス別では、市場はレチノイド、抗生物質、サリチル酸、過酸化ベンゾイルなどに分けられます。レチノイドセグメントはさらに、局所レチノイドおよびレチノイドと経口レチノイドの併用(イソトレチノイン)に分類されます。さらに、抗生物質セグメントは、局所抗生物質と組み合わせ抗生物質および経口抗生物質にさらに細分化されています。

当レポートでは、世界のニキビ治療薬市場について調査し、市場の概要とともに、治療クラス別、処方別、タイプ別、ニキビタイプ別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
    • 主な成功戦略
  • トッププレーヤーのポジショニング、2019
  • 市場力学
    • 促進要因
      • ニキビ病の有病率の増加
      • 不健康な都会のライフスタイル
      • スキンケア製品への注力
    • 抑制要因
      • ニキビ治療薬に関連する副作用
      • ニキビ治療の代替手段の存在
    • 市場機会
      • 新興経済国における機会
      • 副作用の少ない治療法の開発
    • 影響分析
  • 臨床試験
  • 特許分析(2011-2020年)
    • 特許分析:年別
  • ニキビ治療市場に対するCOVID-19の影響

第4章 ニキビ治療薬市場:治療クラス別

  • 概要
    • 市場規模と予測
  • レチノイド
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:タイプ別
      • 局所および併用レチノイド
      • 経口レチノイド(イソトレチノイン)
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 抗生物質
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:タイプ別
      • 局所および併用抗生物質
      • 経口抗生物質
    • 市場規模と予測:地域別
    • 市場分析:国別
  • サリチル酸
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 過酸化ベンゾイル
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別

第5章 ニキビ治療薬市場:処方別

  • 概要
    • 市場規模と予測
  • 局所薬
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 経口薬
    • 市場規模と予測:地域別
    • 市場分析:国別

第6章 ニキビ治療薬市場:タイプ別

  • 概要
    • 市場規模と予測
  • 処方薬
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 市販薬
    • 市場規模と予測:地域別
    • 市場分析:国別

第7章 ニキビ治療薬市場:ニキビタイプ別

  • 概要
    • 市場規模と予測
  • 非炎症性ニキビ
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 炎症性ニキビ
    • 市場規模と予測:地域別
    • 市場分析:国別

第8章 ニキビ治療薬市場:流通チャネル別

  • 概要
    • 市場規模と予測
  • 小売店
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 薬局&ドラッグストア
    • 市場規模と予測:地域別
    • 市場分析:国別
  • eコマース
    • 市場規模と予測:地域別
    • 市場分析:国別

第9章 ニキビ治療薬市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主要な市場動向、成長要因、および機会
    • 北米のニキビ治療薬市場:国別
      • 米国
      • カナダ
      • メキシコ
    • 北米の市場規模と予測:治療クラス別
    • 北米の市場規模と予測:処方別
    • 北米の市場規模と予測:タイプ別
    • 北米の市場規模と予測:ニキビタイプ別
    • 北米の市場規模と予測:流通チャネル別
  • 欧州
    • 主要な市場動向、成長要因、および機会
    • 欧州の市場規模と予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他欧州
    • 欧州の市場規模と予測:治療クラス別
    • 欧州の市場規模と予測:処方別
    • 欧州の市場規模と予測:タイプ別
    • 欧州の市場規模と予測:ニキビタイプ別
    • 欧州の市場規模と予測:流通チャネル別
  • アジア太平洋
    • 主要な市場動向、成長要因、および機会
    • アジア太平洋市場の規模と予測:国別
      • 日本
      • 中国
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域
    • アジア太平洋市場の規模と予測:治療クラス別
    • アジア太平洋市場の規模と予測:処方別
    • アジア太平洋市場のサイズと予測:タイプ別
    • アジア太平洋市場のサイズと予測:ニキビタイプ別
    • アジア太平洋市場の規模と予測:流通チャネル別
  • LAMEA
    • 主要な市場動向、成長要因、および機会
    • LAMEAの市場規模と予測:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ
      • その他LAMEA
    • LAMEAの市場規模と予測:治療クラス別
    • LAMEAの市場規模と予測:処方別
    • LAMEAの市場規模と予測:タイプ別
    • LAMEAの市場規模と予測:ニキビタイプ別
    • LAMEAの市場規模と予測:流通チャネル別

第10章 企業プロファイル

  • ALMIRALL SA
  • BAUSCH HEALTH COMPANIES INC.
  • GLAXOSMITHKLINE PLC (GSK)
  • JOHNSON & JOHNSON
  • GALDERMA S.A.
  • MAYNE PHARMA GROUP LIMITED
  • MYLAN N.V.
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED
  • PFIZER INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
図表

LIST OF TABLES

  • TABLE 01.CLINICAL TRIALS ONGOING IN THE WORLD
  • TABLE 02.ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 03.RETINOID ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 04.TOPICAL RETINOID & COMBINATION RETINOID MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.ORAL RETINOID (ISOTRETINOIN) MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 06.ACNE MEDICATION MARKET FOR RETINOID, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.ANTIBIOTICS ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 08.TOPICAL ANTIBIOTICS & COMBINATION ANTIBIOTICS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.ORAL ANTIBIOTICS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.ANTIBIOTICS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.ACNE MEDICATION MARKET FOR SALICYLIC ACID, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.BENZOYL PEROXIDE MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.ACNE MEDICATION MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.ACNE MEDICATION MARKET, BY FORMULATION, 2019-2027 ($MILLION)
  • TABLE 15.ACNE MEDICATIONS MARKET FOR TOPICAL MEDICATION MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.GLOBAL ACNE MEDICATIONS MARKET, FOR ORAL MEDICATION, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.GLOBAL ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 18.ACNE MEDICATION MARKET FOR PRESCRIPTION MEDICINE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 19.ACNE MEDICATION MARKET FOR OVER-THE-COUNTER, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 21.ACNE MEDICATION MARKET FOR NON-INFLAMMATORY ACNE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 22.ACNE MEDICATION MARKET FOR INFLAMMTORY ACNE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 23.ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 24.GLOBAL ACNE MEDICATION MARKET FOR RETAIL STORE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 25.ACNE MEDICATION MARKET FOR PHARMACY & DRUG STORE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 26.ACNE MEDICATION MARKET FOR E-COMMERCE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 27.ACNE MEDICATION MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 28.NORTH AMERICA ACNE MEDICATION MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 29.U.S. ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 30.U.S. ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 31.U.S. ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 32.U.S. ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 33.CANADA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 34.CANADA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 35.CANADA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 36.CANADA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 37.MEXICO ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 38.MEXICO ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 39.MEXICO ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 40.MEXICO ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 41.NORTH AMERICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 42.NORTH AMERICA ACNE MEDICATION MARKET, BY FORMULATION, 2019-2027 ($MILLION)
  • TABLE 43.NORTH AMERICA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 44.NORTH AMERICA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 45.NORTH AMERICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 46.EUROPE ACNE MEDICATION MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 47.GERMANY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 48.GERMANY ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 49.GERMANY ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 50.GERMANY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 51.FRANCE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 52.FRANCE ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 53.FRANCE ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 54.FRANCE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 55.UK ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 56.UK ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 57.UK ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 58.UK ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 59.ITALY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 60.ITALY ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 61.ITALY ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 62.ITALY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 63.SPAIN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 64.SPAIN ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 65.SPAIN ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 66.SPAIN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 67.REST OF EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 68.REST OF EUROPE ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 69.REST OF EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 70.REST OF EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 71.EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 72.EUROPE ACNE MEDICATION MARKET, BY FORMULATION, 2019-2027 ($MILLION)
  • TABLE 73.EUROPE ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 74.EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 75.EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 76.ASIA-PACIFIC ACNE MEDICATION MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 77.JAPAN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 78.JAPAN ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 79.JAPAN ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 80.JAPAN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 81.CHINA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 82.CHINA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 83.CHINA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 84.CHINA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 85.INDIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 86.INDIA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 87.INDIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 88.INDIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 89.AUSTRALIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 90.AUSTRALIA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 91.AUSTRALIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 92.AUSTRALIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 93.SOUTH KOREA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 94.SOUTH KOREA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 95.SOUTH KOREA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 96.SOUTH KOREA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 97.REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 98.REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 99.REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 100.REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 101.ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 102.ASIA-PACIFIC ACNE MEDICATION MARKET, BY FORMULATION, 2019-2027 ($MILLION)
  • TABLE 103.ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 104.ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 105.ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 106.LAMEA ACNE MEDICATION MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 107.BRAZIL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 108.BRAZIL ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 109.BRAZIL ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 110.BRAZIL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 111.SAUDI ARABIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 112.SAUDI ARABIA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 113.SAUDI ARABIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 114.SAUDI ARABIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 115.SOUTH AFRICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 116.SOUTH AFRICA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 117.SOUTH AFRICA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 118.SOUTH AFRICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 119.REST OF LAMEA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 120.REST OF LAMEA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 121.REST OF LAMEA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 122.REST OF LAMEA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 123.LAMEA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019-2027 ($MILLION)
  • TABLE 124.LAMEA ACNE MEDICATION MARKET, BY FORMULATION, 2019-2027 ($MILLION)
  • TABLE 125.LAMEA ACNE MEDICATION MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 126.LAMEA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019-2027 ($MILLION)
  • TABLE 127.LAMEA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 128.ALMIRALL : COMPANY SNAPSHOT
  • TABLE 129.ALMIRALL: OPERATING SEGMENT
  • TABLE 130.ALMIRAL : PRODUCT PORTFOLIO
  • TABLE 131.ALMIRALL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132.BAUSCH: COMPANY SNAPSHOT
  • TABLE 133.BAUSCH: OPERATING SEGMENTS
  • TABLE 134.BAUSCH: PRODUCT PORTFOLIO
  • TABLE 135.GSK: COMPANY SNAPSHOT
  • TABLE 136.GSK: OPERATING SEGMENTS
  • TABLE 137.GSK: PRODUCT PORTFOLIO
  • TABLE 138.J&J: COMPANY SNAPSHOT
  • TABLE 139.J&J: OPERATING BUSINESS SEGMENTS
  • TABLE 140.J&J: PRODUCT PORTFOLIO
  • TABLE 141.GALDERMA : COMPANY SNAPSHOT
  • TABLE 142.GALDERMA : OPERATING SEGMENTS
  • TABLE 143.GALDERMA : PRODUCT PORTFOLIO
  • TABLE 144.MAYNE PHARMA: COMPANY SNAPSHOT
  • TABLE 145.MAYNE PHARMA: OPERATING SEGMENTS
  • TABLE 146.MAYNE PHARMA: PRODUCT PORTFOLIO
  • TABLE 147.MYLAN: COMPANY SNAPSHOT
  • TABLE 148.MYLAN: OPERATING BUSINESS SEGMENTS
  • TABLE 149.MYLAN: PRODUCT PORTFOLIO
  • TABLE 150.SUN PHARMA: COMPANY SNAPSHOT
  • TABLE 151.SUN PHARMA: OPERATING SEGMENTS
  • TABLE 152.SUN PHARMA: PRODUCT PORTFOLIO
  • TABLE 153.PFIZER: COMPANY SNAPSHOT
  • TABLE 154.PFIZER: OPERATING SEGMENT
  • TABLE 155.PFIZER: PRODUCT PORTFOLIO
  • TABLE 156.TEVA: COMPANY SNAPSHOT
  • TABLE 157.TEVA: OPERATING SEGMENTS
  • TABLE 158.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.ACNE MEDICATION MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2020 *
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2020 (%)
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017-2020
  • FIGURE 06.TOP PLAYER POSITIONING, 2019
  • FIGURE 07.IMPACT ANALYSES
  • FIGURE 08.PATENTS REGISTERED/APPROVED IN THE WORLD, 2011-2020
  • FIGURE 09.PATENTS ANALYSIS BY YEAR, 2018 TO 2020
  • FIGURE 10.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY RETINOIDS MARKET, 2019-2027 ($MILLION)
  • FIGURE 11.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY ANTIBIOTICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY SALICYLIC ACID MARKET, 2019-2027 ($MILLION)
  • FIGURE 13.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY BENZOYL PEROXIDE, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY OTHER, BY REGION, 2019-2027 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY TOPICAL MEDICATION, 2019-2027 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY ORAL MEDICATION, 2019-2027 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY PRESCRIPTION MEDICINES, 2019-2027 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY OVER-THE-COUNTER MEDICINES, 2019-2027 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY NON-INFLAMMATORY ACNE, 2019-2027 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY INFLAMMATORY ACNE, 2019-2027 ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY RETAIL STORE, 2019-2027 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY PHARMACY & DRUG STORE, 2019-2027 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF ACNE MEDICATIONS MARKET, BY E-COMMERCE, 2019-2027 ($MILLION)
  • FIGURE 24.ALMIRALL: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 25.ALMIRALL: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 26.BAUSCH: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 27.BAUSCH: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 28.BAUSCH: REVENUE SHARE, BY REGION , 2019 (%)
  • FIGURE 29.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 30.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 31.GSK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 32.J&J: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 33.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 34.J&J: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 35.MAYNE PHARMA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 36.MAYNE PHARMA: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 37.MAYNE PHARMA: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 38.MYLAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 39.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 40.SUN PHARMA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 41.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 42.SUN PHARMA: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 43.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 44.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 45.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 46.TEVA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 47.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 48.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
目次
Product Code: A04007

Title:
Acne Medication Market by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), Formulation (Topical Medications and Oral Medications), Type (Prescription Medicines and Over-The-Counter Medicines), Acne Type (Non-Inflammatory Acne and Inflammatory Acne), and Distribution Channel (Retail Stores, Pharmacies & Drug Stores, and E-Commerce): Global Opportunity Analysis and Industry Forecast, 2019-2027.

The global acne medication market was valued at $11,865.9 million in 2019, and is projected to reach $13,357.57 million by 2027 at a CAGR of 3.80% from 2020 to 2027.

Acne is a common skin disorder that is mainly caused by excessive production of sebum. In this disorder, there is an outbreak of lesions, which are known as pimples. Acne usually begins at puberty and the condition may worsen during adolescence. It can be treated by acne medications depending upon severity. Acne treatment includes reduction of sebum production, removal of dead skin cells, and killing of bacteria with the help of oral medications and drugs. Acne medications are either applied directly, which are present in formulations or taken in the form of oral pills. These medications work by reducing inflammation and oil production. They also fight with bacteria finally preventing scarring. Common acne medications include retinoids, antibiotics, isotretinoin, and benzoyl peroxide.

Growth of the global acne medication market is driven by rise in prevalence of acne diseases, which is the major factor that contributes toward growth of the acne medication market. Moreover, other factors that fuel the market growth include unhealthy urban lifestyle and presence of robust acne medications in pipeline. However, side-effects associated with the use of acne medications and presence of alternative treatment impede the market growth. Conversely, development of effective medications with lesser side effects and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market growth.

The global acne medication market is segmented into therapeutic class, formulation, type, acne type, distribution channel, and region. By therapeutic class, the market is divided into retinoids, antibiotics, salicylic acid, benzoyl peroxide, and others. The retinoids segment is further classified into topical retinoid & combination retinoid and oral retinoid (isotretinoin). Moreover, the antibiotics segment is further sub-segmented into topical antibiotics & combination antibiotics and oral antibiotics.

On the basis of formulation, the market is bifurcated into topical medication and oral medication. By type, it is divided into prescription medicine and over-the-counter (OTC) medicine. By acne type, it is fragmented into non-inflammatory and inflammatory acne. By distribution channel, it is classified into retail store, pharmacy & drug store, and e-commerce. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify prevailing opportunities along with strategic assessment of the global acne medication market.

Market size and estimations are based on a comprehensive analysis of end users, developments, and services in the industry.

An in-depth analysis based on region assists to understand the regional market and facilitates strategic business planning.

Developmental strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

  By Therapeutic Class

Retinoid

Topical Retinoid & Combination Retinoid

Oral Retinoid (Isotretinoin)

Antibiotic

Topical Antibiotic & Combination Antibiotics

Oral Antibiotics

Salicylic Acid

Benzoyl Peroxide

Others

By Formulation

  • Topical Medication
  • Oral Medication

By Type

  • Prescription Medicine
  • Over-the-counter (OTC) Medicine

By Acne Type

  • Inflammatory Acne
  • Non-inflammatory Acne

By Distribution Channel

  • Retail Store
  • Pharmacy & Drug Store
  • E-Commerce

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • KEY MARKET PLAYERS
  • Almirall SA.
  • Bausch Health Companies Inc.
  • GlaxoSmithKline Plc (GSK)
  • Johnson & Johnson
  • Galderma S.A
  • Mayne Pharma Group Limited
  • Mylan N.V.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.List of key players profiled in the report
  • 1.5.Research methodology
    • 1.5.1.Secondary research
    • 1.5.2.Primary research
    • 1.5.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Top player positioning, 2019
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Increase in prevalence of acne diseases
      • 3.4.1.2.Unhealthy urban lifestyle
      • 3.4.1.3.Rise in focus on skin care products
    • 3.4.2.Restraints
      • 3.4.2.1.Side effects associated with acne medications
      • 3.4.2.2.Presence of alternatives for acne treatment
    • 3.4.3.Opportunities
      • 3.4.3.1.Opportunities in emerging economies
      • 3.4.3.2.Development of therapeutics with lesser side effects
    • 3.4.4.Impact analyses
  • 3.5.Clinical trials
  • 3.6.Patent analysis (2011-2020)
    • 3.6.1.Patent analysis, by year
  • 3.7.Impact of COVID-19 on Acne Medication Market

CHAPTER 4:ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Retinoid
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by type
      • 4.2.2.1.Topical & combination retinoids
      • 4.2.2.1.1.Market size and forecast, by region
      • 4.2.2.2.Oral retinoid (Isotretinoin)
      • 4.2.2.2.1.Market size and forecast, by region
    • 4.2.3.Market size and forecast, by region
    • 4.2.4.Market analysis, by country
  • 4.3.Antibiotics
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by type
      • 4.3.2.1.Topical & combination antibiotics
      • 4.3.2.1.1.Market size and forecast, by region
      • 4.3.2.2.Oral antibiotics
      • 4.3.2.2.1.Market size and forecast, by region
    • 4.3.3.Market size and forecast, by region
    • 4.3.4.Market analysis, by country
  • 4.4.Salicylic acid
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Benzoyl Peroxide
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Other medications
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country

CHAPTER 5:ACNE MEDICATION MARKET, BY FORMULATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Topical medications
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Oral medications
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:ACNE MEDICATION MARKET, BY TYPE

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Prescription medicines
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Over-the-counter medicines
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country

CHAPTER 7:ACNE MEDICATION MARKET, BY ACNE TYPE

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.Non-inflammatory acne
    • 7.2.1.Market size and forecast, by region
    • 7.2.2.Market analysis, by country
  • 7.3.Inflammatory acne
    • 7.3.1.Market size and forecast, by region
    • 7.3.2.Market analysis, by country

CHAPTER 8:ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL

  • 8.1.Overview
    • 8.1.1.Market size and forecast
  • 8.2.Retail store
    • 8.2.1.Market size and forecast, by region
    • 8.2.2.Market analysis, by country
  • 8.3.Pharmacy & drug store
    • 8.3.1.Market size and forecast, by region
    • 8.3.2.Market analysis, by country
  • 8.4.E-Commerce
    • 8.4.1.Market size and forecast, by region
    • 8.4.2.Market analysis, by country

CHAPTER 9:ACNE MEDICATION MARKET, BY REGION

  • 9.1.Overview
    • 9.1.1.Market size and forecast
  • 9.2.North America
    • 9.2.1.Key market trends, growth factors, and opportunities
    • 9.2.2.North America acne medication market, by country
      • 9.2.2.1.U.S.
      • 9.2.2.1.1.Market size and forecast, by therapeutic class
      • 9.2.2.1.2.Market size and forecast, by type
      • 9.2.2.1.3.Market size and forecast, by acne type
      • 9.2.2.1.4.Market size and forecast, by distribution channel
      • 9.2.2.2.Canada
      • 9.2.2.2.1.Market size and forecast, by therapeutic class
      • 9.2.2.2.2.Market size and forecast, by type
      • 9.2.2.2.3.Market size and forecast, by acne type
      • 9.2.2.2.4.Market size and forecast, by distribution channel
      • 9.2.2.3.Mexico
      • 9.2.2.3.1.Market size and forecast, by therapeutic class
      • 9.2.2.3.2.Market size and forecast, by type
      • 9.2.2.3.3.Market size and forecast, by acne type
      • 9.2.2.3.4.Market size and forecast, by distribution channel
    • 9.2.3.North America market size and forecast, by therapeutic class
    • 9.2.4.North America market size and forecast, by formulation
    • 9.2.5.North America market size and forecast, by type
    • 9.2.6.North America market size and forecast, by acne type
    • 9.2.7.North America market size and forecast, by distribution channel
  • 9.3.Europe
    • 9.3.1.Key market trends, growth factors, and opportunities
    • 9.3.2.Europe market size and forecast, by country
      • 9.3.2.1.Germany
      • 9.3.2.1.1.Market size and forecast, by therapeutic class
      • 9.3.2.1.2.Market size and forecast, by type
      • 9.3.2.1.3.Market size and forecast, by acne type
      • 9.3.2.1.4.Market size and forecast, by distribution channel
      • 9.3.2.2.France
      • 9.3.2.2.1.Market size and forecast, by therapeutic class
      • 9.3.2.2.2.Market size and forecast, by type
      • 9.3.2.2.3.Market size and forecast, by acne type
      • 9.3.2.2.4.Market size and forecast, by distribution channel
      • 9.3.2.3.UK
      • 9.3.2.3.1.Market size and forecast, by therapeutic class
      • 9.3.2.3.2.Market size and forecast, by type
      • 9.3.2.3.3.Market size and forecast, by acne type
      • 9.3.2.3.4.Market size and forecast, by distribution channel
      • 9.3.2.4.Italy
      • 9.3.2.4.1.Market size and forecast, by therapeutic class
      • 9.3.2.4.2.Market size and forecast, by type
      • 9.3.2.4.3.Market size and forecast, by acne type
      • 9.3.2.4.4.Market size and forecast, by distribution channel
      • 9.3.2.5.Spain
      • 9.3.2.5.1.Market size and forecast, by therapeutic class
      • 9.3.2.5.2.Market size and forecast, by type
      • 9.3.2.5.3.Market size and forecast, by acne type
      • 9.3.2.5.4.Market size and forecast, by distribution channel
      • 9.3.2.6.Rest of Europe
      • 9.3.2.6.1.Market size and forecast, by therapeutic class
      • 9.3.2.6.2.Market size and forecast, by type
      • 9.3.2.6.3.Market size and forecast, by acne type
      • 9.3.2.6.4.Market size and forecast, by distribution channel
    • 9.3.3.Europe market size and forecast, by therapeutic class
    • 9.3.4.Europe market size and forecast, by formulation
    • 9.3.5.Europe market size and forecast, by type
    • 9.3.6.Europe market size and forecast, by acne type
    • 9.3.7.Europe market size and forecast, by distribution channel
  • 9.4.Asia-Pacific
    • 9.4.1.Key market trends, growth factors, and opportunities
    • 9.4.2.Asia-Pacific market size and forecast, by country
      • 9.4.2.1.Japan
      • 9.4.2.1.1.Market size and forecast, by therapeutic class
      • 9.4.2.1.2.Market size and forecast, by type
      • 9.4.2.1.3.Market size and forecast, by acne type
      • 9.4.2.1.4.Market size and forecast, by distribution channel
      • 9.4.2.2.China
      • 9.4.2.2.1.Market size and forecast, by therapeutic class
      • 9.4.2.2.2.Market size and forecast, by type
      • 9.4.2.2.3.Market size and forecast, by acne type
      • 9.4.2.2.4.Market size and forecast, by distribution channel
      • 9.4.2.3.India
      • 9.4.2.3.1.Market size and forecast, by therapeutic class
      • 9.4.2.3.2.Market size and forecast, by type
      • 9.4.2.3.3.Market size and forecast, by acne type
      • 9.4.2.3.4.Market size and forecast, by distribution channel
      • 9.4.2.4.Australia
      • 9.4.2.4.1.Market size and forecast, by therapeutic class
      • 9.4.2.4.2.Market size and forecast, by type
      • 9.4.2.4.3.Market size and forecast, by acne type
      • 9.4.2.4.4.Market size and forecast, by distribution channel
      • 9.4.2.5.South Korea
      • 9.4.2.5.1.Market size and forecast, by therapeutic class
      • 9.4.2.5.2.Market size and forecast, by type
      • 9.4.2.5.3.Market size and forecast, by acne type
      • 9.4.2.5.4.Market size and forecast, by distribution channel
      • 9.4.2.6.Rest of Asia-Pacific
      • 9.4.2.6.1.Market size and forecast, by therapeutic class
      • 9.4.2.6.2.Market size and forecast, by type
      • 9.4.2.6.3.Market size and forecast, by acne type
      • 9.4.2.6.4.Market size and forecast, by distribution channel
    • 9.4.3.Asia-Pacific market size and forecast, by therapeutic class
    • 9.4.4.Asia-Pacific market size and forecast, by formulation
    • 9.4.5.Asia-Pacific market size and forecast, by type
    • 9.4.6.Asia-Pacific market size and forecast, by acne type
    • 9.4.7.Asia-Pacific market size and forecast, by distribution channel
  • 9.5.LAMEA
    • 9.5.1.Key market trends, growth factors, and opportunities
    • 9.5.2.LAMEA market size and forecast, by country
      • 9.5.2.1.Brazil
      • 9.5.2.1.1.Market size and forecast, by therapeutic class
      • 9.5.2.1.2.Market size and forecast, by type
      • 9.5.2.1.3.Market size and forecast, by acne type
      • 9.5.2.1.4.Market size and forecast, by distribution channel
      • 9.5.2.2.Saudi Arabia
      • 9.5.2.2.1.Market size and forecast, by therapeutic class
      • 9.5.2.2.2.Market size and forecast, by type
      • 9.5.2.2.3.Market size and forecast, by acne type
      • 9.5.2.2.4.Market size and forecast, by distribution channel
      • 9.5.2.3.South Africa
      • 9.5.2.3.1.Market size and forecast, by therapeutic class
      • 9.5.2.3.2.Market size and forecast, by type
      • 9.5.2.3.3.Market size and forecast, by acne type
      • 9.5.2.3.4.Market size and forecast, by distribution channel
      • 9.5.2.4.Rest of LAMEA
      • 9.5.2.4.1.Market size and forecast, by therapeutic class
      • 9.5.2.4.2.Market size and forecast, by type
      • 9.5.2.4.3.Market size and forecast, by acne type
      • 9.5.2.4.4.Market size and forecast, by distribution channel
    • 9.5.3.LAMEA market size and forecast, by therapeutic class
    • 9.5.4.LAMEA market size and forecast, by formulation
    • 9.5.5.LAMEA market size and forecast, by type
    • 9.5.6.LAMEA market size and forecast, by acne type
    • 9.5.7.LAMEA market size and forecast, by distribution channel

CHAPTER 10:COMPANY PROFILES

  • 10.1.ALMIRALL SA
    • 10.1.1.Company overview
    • 10.1.2.Company snapshot
    • 10.1.3.Operating business segments
    • 10.1.4.Product portfolio
    • 10.1.5.Business performance
    • 10.1.6.Key strategic moves and developments
  • 10.2.BAUSCH HEALTH COMPANIES INC.
    • 10.2.1.Company overview
    • 10.2.2.Company snapshot
    • 10.2.3.Operating business segments
    • 10.2.4.Product portfolio
    • 10.2.5.Business performance
    • 10.2.6.Key strategic moves and developments
  • 10.3.GLAXOSMITHKLINE PLC (GSK)
    • 10.3.1.Company overview
    • 10.3.2.Company snapshot
    • 10.3.3.Operating business segments
    • 10.3.4.Product portfolio
    • 10.3.5.Business performance.
  • 10.4.JOHNSON & JOHNSON
    • 10.4.1.Company overview
    • 10.4.2.Company snapshot
    • 10.4.3.Operating business segments
    • 10.4.4.Product portfolio
    • 10.4.5.Business performance
  • 10.5.GALDERMA S.A.
    • 10.5.1.Company overview
    • 10.5.2.Company snapshot
    • 10.5.3.Operating business segments
    • 10.5.4.Product portfolio
    • 10.5.5.Key strategic moves and developments
  • 10.6.MAYNE PHARMA GROUP LIMITED
    • 10.6.1.Company overview
    • 10.6.2.Company snapshot
    • 10.6.3.Operating business segments
    • 10.6.4.Product portfolio
    • 10.6.5.Business performance
    • 10.6.6.Key strategic moves and developments
  • 10.7.MYLAN N.V.
    • 10.7.1.Company overview
    • 10.7.2.Company snapshot
    • 10.7.3.Operating business segments
    • 10.7.4.Product portfolio
    • 10.7.5.Business performance
  • 10.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED
    • 10.8.1.Company overview
    • 10.8.2.Company snapshot
    • 10.8.3.Operating business segments
    • 10.8.4.Product portfolio
    • 10.8.5.Business performance
    • 10.8.6.Key strategic moves and developments
  • 10.9.PFIZER INC.
    • 10.9.1.Company overview
    • 10.9.2.Company snapshot
    • 10.9.3.Operating business segments
    • 10.9.4.Product portfolio
    • 10.9.5.Business performance
  • 10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 10.10.1.Company overview
    • 10.10.2.Company snapshot
    • 10.10.3.Operating business segments
    • 10.10.4.Product portfolio
    • 10.10.5.Business performance
    • 10.10.6.Key strategic moves and developments